Deutsche Bank analyst Justin Bowers raised the firm’s price target on West Pharmaceutical (WST) to $345 from $305 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WST:
- West Pharmaceutical Services Reports Strong Q3 2025 Results
- West Pharmaceutical Services’ Earnings Call: Optimistic Growth Amid Challenges
- West Pharmaceutical price target raised to $390 from $350 at Evercore ISI
- Early notable gainers among liquid option names on October 23rd
- Strong Q3 Performance and Raised 2025 Guidance Justify Buy Rating for West Pharmaceutical Services